Henrik Loft

4.0k total citations
60 papers, 3.0k citations indexed

About

Henrik Loft is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Henrik Loft has authored 60 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pharmacology, 27 papers in Experimental and Cognitive Psychology and 17 papers in Psychiatry and Mental health. Recurrent topics in Henrik Loft's work include Treatment of Major Depression (38 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (18 papers) and Mental Health Research Topics (13 papers). Henrik Loft is often cited by papers focused on Treatment of Major Depression (38 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (18 papers) and Mental Health Research Topics (13 papers). Henrik Loft collaborates with scholars based in Denmark, United States and United Kingdom. Henrik Loft's co-authors include Elin Heldbo Reines, Ioana Florea, Ulla Lepola, Marianne Dragheim, Jean‐Philippe Boulenger, S. Bakchine, Michael Cronquist Christensen, Roger S. McIntyre, Serge Gauthier and David S. Baldwin and has published in prestigious journals such as Neurology, The British Journal of Psychiatry and Journal of Affective Disorders.

In The Last Decade

Henrik Loft

58 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henrik Loft Denmark	29	1.8k	1.1k	923	543	423	60	3.0k
Charles DeBattista United States	35	1.7k 0.9×	824 0.8×	1.3k 1.4×	1.1k 2.1×	670 1.6×	90	4.1k
J. Craig Nelson United States	33	1.3k 0.7×	613 0.6×	1.4k 1.6×	476 0.9×	431 1.0×	87	3.2k
S. Danielle Canada	33	1.5k 0.8×	838 0.8×	1.2k 1.3×	1.1k 2.1×	682 1.6×	80	3.9k
Esa Leìnonen Finland	32	1000 0.6×	545 0.5×	1.7k 1.8×	548 1.0×	424 1.0×	161	3.6k
J. Craig Nelson United States	30	1.2k 0.7×	543 0.5×	1.4k 1.5×	563 1.0×	229 0.5×	55	3.4k
Armin Szegedi Germany	40	1.3k 0.7×	784 0.7×	2.3k 2.5×	407 0.7×	551 1.3×	120	4.6k
Chiara Fabbri Italy	31	1.2k 0.6×	494 0.5×	1.0k 1.1×	900 1.7×	300 0.7×	155	3.1k
Manish K. Jha United States	30	1.3k 0.7×	741 0.7×	664 0.7×	1.3k 2.3×	519 1.2×	167	3.3k
Joel Raskin United States	35	1.9k 1.0×	743 0.7×	1.6k 1.7×	282 0.5×	638 1.5×	86	4.5k
Neven Henigsberg Croatia	21	831 0.5×	709 0.7×	496 0.5×	807 1.5×	362 0.9×	79	2.4k

Countries citing papers authored by Henrik Loft

Since Specialization

Citations

This map shows the geographic impact of Henrik Loft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Loft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Loft more than expected).

Fields of papers citing papers by Henrik Loft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrik Loft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Loft. The network helps show where Henrik Loft may publish in the future.

Co-authorship network of co-authors of Henrik Loft

This figure shows the co-authorship network connecting the top 25 collaborators of Henrik Loft. A scholar is included among the top collaborators of Henrik Loft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrik Loft. Henrik Loft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Christensen, Michael Cronquist, et al.. (2023). Clinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder. CNS Spectrums. 28(6). 693–701. 13 indexed citations

Christensen, Michael Cronquist, et al.. (2023). Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability. Journal of Affective Disorders. 328. 345–354. 18 indexed citations

Müller‐Vahl, Kirsten, et al.. (2021). Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study. Pharmacopsychiatry. 55(3). 148–156. 21 indexed citations

Nierenberg, Andrew A., Henrik Loft, & C.K. Olsen. (2019). Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders. 250. 35–42. 22 indexed citations

Christensen, Michael Cronquist, Ioana Florea, Henrik Loft, & Roger S. McIntyre. (2019). Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. Journal of Affective Disorders. 263. 258–266. 17 indexed citations

Christensen, Michael Cronquist, Henrik Loft, & Roger S. McIntyre. (2017). Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. Journal of Affective Disorders. 227. 787–794. 35 indexed citations

Saragoussi, Delphine, Maëlys Touya, Josep María Haro, et al.. (2017). Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatric Disease and Treatment. Volume 13. 2151–2165. 46 indexed citations

McIntyre, Roger S., et al.. (2016). Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. The Journal of Clinical Psychiatry. 78(1). 115–121. 84 indexed citations

Naik, Himanshu, Majid Vakilynejad, Grace Chen, et al.. (2015). A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic & Clinical Pharmacology & Toxicology. 118(5). 344–355. 8 indexed citations

10.

Florea, Ioana, Natalya Danchenko, Mélanie Brignone, et al.. (2015). The Effect of Vortioxetine on Health-related Quality of Life in Patients With Major Depressive Disorder. Clinical Therapeutics. 37(10). 2309–2323.e6. 24 indexed citations

11.

Florea, Ioana, et al.. (2013). The effect of vortioxetine (LU AA21004) on health-related quality of life (HRQOL) in patients with major depressive disorder (MDD). Value in Health. 16(3). A65–A65. 1 indexed citations

12.

Baldwin, David S., Henrik Loft, & Ioana Florea. (2012). Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. International Clinical Psychopharmacology. 27(4). 197–207. 39 indexed citations

13.

Álvarez, Enric, Víctor Pérez, Marianne Dragheim, Henrik Loft, & Francesc Artigas. (2011). A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. The International Journal of Neuropsychopharmacology. 15(5). 589–600. 180 indexed citations

14.

Hajak, Göran, et al.. (2009). A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients. Sleep Medicine. 10(7). 705–712. 23 indexed citations

15.

Wilcock, Gordon, Clive Ballard, James A. Cooper, & Henrik Loft. (2008). Memantine for Agitation/Aggression and Psychosis in Moderately Severe to Severe Alzheimer's Disease. The Journal of Clinical Psychiatry. 69(3). 341–348. 160 indexed citations

16.

Gauthier, Serge, Henrik Loft, & Jeffrey L. Cummings. (2007). Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry. 23(5). 537–545. 167 indexed citations

17.

Kasper, Siegfried, Dan J. Stein, Henrik Loft, & R. Nil. (2005). Escitalopram in the treatment of social anxiety disorder. The British Journal of Psychiatry. 186(3). 222–226. 96 indexed citations

18.

Montgomery, Stuart, Henrik Loft, Connie Sánchez, Elin Heldbo Reines, & Mariusz Papp. (2001). Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model. Pharmacology & Toxicology. 88(5). 282–286. 126 indexed citations

19.

Guelfi, J.D., et al.. (2000). Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Journal of Affective Disorders. 58(3). 201–209. 25 indexed citations

20.

Kristensen, Bent Bruun, Bent Ejlertsen, M. Groenvold, et al.. (1999). Oral clodronate in breast cancer patients with bone metastases: a randomized study. Journal of Internal Medicine. 246(1). 67–74. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact